Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge

Vaccine

Volumn 31, Issue 2, 2013, Pages 319-326

  Xiao, Yuhong ^a   Zeng, Yuhong ^b,d   Alexander, Edward ^a   Mehta, Shyam ^b   Joshi, Sangeeta B ^b   Buchman, George W ^c   Volkin, David B ^b   Russell Middaugh, C ^b,e   Isaacs, Stuart N ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c Chesapeake PERL Inc   (United States)

^d ALCON RESEARCH LTD   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Adjuvants, immunologic ; Adsorption; Aluminum hydroxide; Animals; Antibody formation immunology; Antigens chemistry ; Formulation; immunology; pharmacology; Phosphates immunology ; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; POXVIRUS L1 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE;

ADSORPTION; ANIMAL EXPERIMENT; ARTICLE; BACULOVIRUS; CONTROLLED STUDY; DRUG DESIGN; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PH; POXVIRUS; PRIORITY JOURNAL; SURVIVAL; TEMPERATURE; WEIGHT REDUCTION;

ADJUVANTS, IMMUNOLOGIC; ADSORPTION; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODY FORMATION; DNA-BINDING PROTEINS; FEMALE; MICE; MICE, INBRED BALB C; POXVIRIDAE; RECOMBINANT PROTEINS; SMALLPOX VACCINE; VACCINES, SUBUNIT; VACCINIA; VACCINIA VIRUS; VIRAL CORE PROTEINS;

EID: 84871366369     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.007     Document Type: Article

References (42)

1. Baylor N.W., Egan W., Richman P. Aluminum salts in vaccines - US perspective. Vaccine 2002, 20(Suppl. 3):S18-S23.
2. Brewer J.M. (How) do aluminium adjuvants work?. Immunol Lett 2006, 102(1):10-15.
3. WHO Immunological adjuvants. Report of a WHO scientific group. World Health Organ Tech Rep Ser 1976, 595:1-40.
4. Flach T.L., Ng G., Hari A., Desrosiers M.D., Zhang P., Ward S.M., et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011, 17(4):479-487.
5. Hansen B., Sokolovska A., HogenEsch H., Hem S.L. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine 2007, 25(36):6618-6624.
6. Hem S.L., Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007, 6(5):685-698.
7. Hansen B., Belfast M., Soung G., Song L., Egan P.M., Capen R., et al. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. Vaccine 2009, 27(6):888-892.
8. Hansen B., Malyala P., Singh M., Sun Y., Srivastava I., Hogenesch H., et al. Effect of the strength of adsorption of HIV 1 SF162dV2gp140 to aluminum-containing adjuvants on the immune response. J Pharm Sci 2011, 100(8):3245-3250.
9. Chang M., Shi Y., Nail S.L., HogenEsch H., Adams S.B., White J.L., et al. Degree of antigen adsorption in the vaccine or interstitial fluid and its effect on the antibody response in rabbits. Vaccine 2001, 19(20-22):2884-2889.
10. Iyer S., HogenEsch H., Hem S.L. Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production. Vaccine 2003, 21(11-12):1219-1223.
11. Berthold I., Pombo M.L., Wagner L., Arciniega J.L. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants. Vaccine 2005, 23(16):1993-1999.
12. Romero Mendez I.Z., Shi Y., HogenEsch H., Hem S.L. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine 2007, 25(5):825-833.
13. Noe S.M., Green M.A., HogenEsch H., Hem S.L. Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response. Vaccine 2010, 28(20):3588-3594.
14. Seeber S.J., White J.L., Hem S.L. Solubilization of aluminum-containing adjuvants by constituents of interstitial fluid. J Parenter Sci Technol 1991, 45(3):156-159.
15. Heimlich J.M., Regnier F.E., White J.L., Hem S.L. The in vitro displacement of adsorbed model antigens from aluminium-containing adjuvants by interstitial proteins. Vaccine 1999, 17(22):2873-2881.
16. Jiang D., Morefield G.L., HogenEsch H., Hem S.L. Relationship of adsorption mechanism of antigens by aluminum-containing adjuvants to in vitro elution in interstitial fluid. Vaccine 2006, 24(10):1665-1669.
17. Xiao Y., Aldaz-Carroll L., Ortiz A.M., Whitbeck J.C., Alexander E., Lou H., et al. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 2007, 25:1214-1224.
18. Buchman G.W., Cohen M.E., Xiao Y., Richardson-Harman N., Silvera P., DeTolla L.J., et al. A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine 2010, 28(40):6627-6636.
19. Cohen M.E., Xiao Y., Eisenberg R.J., Cohen G.H., Isaacs S.N. Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors. PLoS One 2011, 6(6):e20597.
20. Hooper J.W., Custer D.M., Schmaljohn C.S., Schmaljohn A.L. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 2000, 266:329-339.
21. Hooper J.W., Custer D.M., Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 2003, 306(1):181-195.
22. Fogg C., Lustig S., Whitbeck J.C., Eisenberg R.J., Cohen G.H., Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol 2004, 78(19):10230-10237.
23. Hooper J.W., Thompson E., Wilhelmsen C., Zimmerman M., Ichou M.A., Steffen S.E., et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol 2004, 78(9):4433-4443.
24. Sakhatskyy P., Wang S., Chou T.H., Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 2006, 355(2):164-174.
25. Fogg C.N., Americo J.L., Lustig S., Huggins J.W., Smith S.K., Damon I., et al. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine 2007, 25(15):2787-2799.
26. Golden J.W., Josleyn M.D., Hooper J.W. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Vaccine 2008, 26(27-28):3507-3515.
27. Sakhatskyy P., Wang S., Zhang C., Chou T.H., Kishko M., Lu S. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology 2008, 371(1):98-107.
28. Hooper J.W., Ferro A.M., Golden J.W., Silvera P., Dudek J., Alterson K., et al. Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine 2009, 28:494-511.
29. Aldaz-Carroll L., Whitbeck J.C., Ponce de Leon M., Lou H., Pannell L.K., Lebowitz J., et al. Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology 2005, 341(1):59-71.
30. Joshi S.B., Bhambhani A., Zeng Y., Middaugh C.R. An empirical phase diagram/high throughput screening approach to the characterization and formulation of biopharmaceuticals. Formulation and process development strategies for manufacturing biopharmaceuticals 2010, 173-204. Wiley & Sons, New York. F. Jameel, S. Hershenson (Eds.).
31. Maddux N.R., Joshi S.B., Volkin D.B., Ralston J.P., Middaugh C.R. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci 2011, 100(10):4171-4197.
32. Fang M., Cheng H., Dai Z., Bu Z., Sigal L.J. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology 2006, 345(1):231-243.
33. Pullen G.R., Fitzgerald M.G., Hosking C.S. Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods 1986, 86(1):83-87.
34. Su H.P., Garman S.C., Allison T.J., Fogg C., Moss B., Garboczi D.N. The 1.51-Angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies. Proc Natl Acad Sci USA 2005, 102(12):4240-4245.
35. Hem S.L., HogenEsch H., Middaugh C.R., Volkin D.B. Preformulation studies - The next advance in aluminum adjuvant-containing vaccines. Vaccine 2010, 28(31):4868-4870.
36. Volkin D.B., Middaugh C.R. Vaccines as physically and chemically well-defined pharmaceutical dosage forms. Expert Rev Vaccines 2010, 9(7):689-691.
37. Levesque P.M., Foster K., de Alwis U. Association between immunogenicity and adsorption of a recombinant Streptococcus pneumoniae vaccine antigen by an aluminum adjuvant. Hum Vaccin 2006, 2(2):74-77.
38. Jones L.S., Peek L.J., Power J., Markham A., Yazzie B., Middaugh C.R. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem 2005, 280(14):13406-13414.
39. Peek L.J., Martin T.T., Elk Nation C., Pegram S.A., Middaugh C.R. Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. J Pharm Sci 2007, 96(3):547-557.
40. Benhnia M.R., McCausland M.M., Laudenslager J., Granger S.W., Rickert S., Koriazova L., et al. Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5. J Virol 2009, 83(23):12355-12367.
41. Benhnia M.R., McCausland M.M., Moyron J., Laudenslager J., Granger S., Rickert S., et al. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol 2009, 83(3):1201-1215.
42. Panchanathan V., Chaudhri G., Karupiah G. Correlates of protective immunity in poxvirus infection: where does antibody stand?. Immunol Cell Biol 2008, 86(1):80-86.